Martina Bedeschi

Meldola, 47014, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Sustainable chemistry and preclinical characterization of RC-106·HCl: A brain-penetrant pan sigma receptor modulator for glioblastoma.

Sustainable chemistry and preclinical characterization of RC-106·HCl: A brain-penetrant pan sigma receptor modulator for glioblastoma.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: January 23, 2026

Correction: Bedeschi et al. Glioblastoma Tumor Microenvironment and Purinergic Signaling: Implications for Novel Therapies. Pharmaceuticals 2025, 18, 385.

Correction: Bedeschi et al. Glioblastoma Tumor Microenvironment and Purinergic Signaling: Implications for Novel Therapies. Pharmaceuticals 2025, 18, 385.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: September 29, 2025

Development of a 3D bioprinted human skin model for predictive toxicology.

Development of a 3D bioprinted human skin model for predictive toxicology.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: August 26, 2025

Preparation of a Micronutrient-Enriched Apricot Kernel Oil and Assessment of In Vitro Chemopreventive Properties.

Preparation of a Micronutrient-Enriched Apricot Kernel Oil and Assessment of In Vitro Chemopreventive Properties.

Journal: International journal of molecular sciences

Published: August 11, 2025

Redefine tumor spheroids heterogeneity via PCA-coupled biophysical characterization.

Redefine tumor spheroids heterogeneity via PCA-coupled biophysical characterization.

Journal: Scientific reports

Published: June 12, 2025

Glioblastoma Tumor Microenvironment and Purinergic Signaling: Implications for Novel Therapies.

Glioblastoma Tumor Microenvironment and Purinergic Signaling: Implications for Novel Therapies.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: January 24, 2025

A step-by-step protocol based on data mining to explore purinergic signaling in glioblastoma.

A step-by-step protocol based on data mining to explore purinergic signaling in glioblastoma.

Journal: Purinergic signalling

Published: November 27, 2024

Glitches in the brain: the dangerous relationship between radiotherapy and brain fog.

Glitches in the brain: the dangerous relationship between radiotherapy and brain fog.

Journal: Frontiers in cellular neuroscience

Published: October 26, 2023

Galantamine-memantine hybrids for Alzheimer's disease: The influence of linker rigidity in biological activity and pharmacokinetic properties.

Galantamine-memantine hybrids for Alzheimer's disease: The influence of linker rigidity in biological activity and pharmacokinetic properties.

Journal: European journal of medicinal chemistry

Published: July 11, 2023

Discovery of RC-752, a Novel Sigma-1 Receptor Antagonist with Antinociceptive Activity: A Promising Tool for Fighting Neuropathic Pain.

Discovery of RC-752, a Novel Sigma-1 Receptor Antagonist with Antinociceptive Activity: A Promising Tool for Fighting Neuropathic Pain.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: May 30, 2023

Genome-wide profiling of patient-derived glioblastoma stem-like cells reveals recurrent genetic and transcriptomic signatures associated with brain tumors.

Genome-wide profiling of patient-derived glioblastoma stem-like cells reveals recurrent genetic and transcriptomic signatures associated with brain tumors.

Journal: Journal of neuro-oncology

Published: January 31, 2023

Cancer-Associated Fibroblast: Role in Prostate Cancer Progression to Metastatic Disease and Therapeutic Resistance.

Cancer-Associated Fibroblast: Role in Prostate Cancer Progression to Metastatic Disease and Therapeutic Resistance.

Journal: Cells

Published: January 30, 2023

Showing 1-12 of 15

Last Updated: 09/26/2026